ROBOTICS & AUTOMATION
Empowering Progress
Up to 25% off Essentials Robotics and Automation titles
Annual Reports in Medicinal Chemistry
- 1st Edition, Volume 47 - October 8, 2012
- Editor: John E. Macor
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 3 9 6 4 9 2 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 3 9 7 2 1 4 - 9
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biolog… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAnnual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
- Timely and critical reviews of important topics in medicinal chemistry
Medicinal, pharmaceutical, and organic chemists
Contributors
Preface
Chapter One Reflections on Medicinal Chemistry at Merck, West Point
Chapter Two My Path in Seeking New Medicines
Reflections
Chapter Three Tales of Drug Discovery
1 Prostaglandins
2 Cannabinoid Analgesics
3 Hypoglycemic Agents
4 Opioid Analgesics
5 HIV Fusion Inhibitors
6 Epithelial Sodium Channel Blockers
7 Conclusions and Ramblings
Chapter Four Recent Developments in Targeting Neuroinflammation in Disease
1 Introduction
2 Ion Channels
3 Enzymes
4 Receptors
5 Concluding Remarks
Chapter Five Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer’s Disease
1 Introduction
2 Inhibitors of GS
3 Modulators of GS
4 Inhibitors of β-Secretase
5 Concluding Remarks
Chapter Six mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
1 Introduction
2 Discovery and Development of mGluR2 Activators
3 Drug Discovery and Development of mGluR5 NAMs
4 Conclusion
Chapter Seven NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments
1 Introduction
2 X-ray Structural Studies and Homology Modeling of NMDA Receptors
3 Channel Blockers
4 Inhibitors of GluN2B Subtype Receptor
5 Inhibitors and Modulators of GluN2A, GluN2C, and GluN2D Subtype Receptors
6 Clinical Trials
7 Conclusions
Chapter Eight Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
1 Introduction
2 PET and SPECT
3 CNS PET Tracers: General Requirements and Key Hurdles
4 Recent Advances in CNS PET Tracer Development
5 New CNS PET Tracers
6 SPECT in Brain Imaging
7 Conclusions
Chapter Nine Case History
1 Introduction
2 Rationale for Targeting FXa
3 Medicinal Chemistry Efforts Culminating in Apixaban
4 Preclinical Properties of Apixaban
5 Clinical Studies of Apixaban
6 Conclusion
Chapter Ten AMPK Activation in Health and Disease
1 Introduction
2 AMPK—Enzyme Structure and Function
3 Major AMPK-Mediated Effects on Lipid and Carbohydrate Metabolism
4 Therapeutic Potential of AMPK Activation
5 Pharmacological AMPK Activators
6 Conclusion
Chapter Eleven Type-2 Diabetes and Associated Comorbidities as an Inflammatory Syndrome
1 Introduction
2 Type-2 Diabetes
3 Diabetic Nephropathy
4 Diabetic Retinopathy
5 Diabetic Neuropathy
6 Conclusions
Chapter Twelve Beyond PPARs and Metformin
1 Introduction
2 Insulin Sensitizers
3 Conclusion
Chapter Thirteen Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
1 Introduction
2 Recent Clinical Developments of S1P1 Agonists
3 Recent Preclinical Developments of S1P1 Agonists
4 Conclusions
Chapter Fourteen Bifunctional Compounds for the Treatment of COPD
1 Introduction
2 Bifunctional Strategies and Compounds
3 Conclusions
Chapter Fifteen Inflammatory Targets for the Treatment of Atherosclerosis
1 Introduction
2 Phospholipase A2
3 Leukotriene Pathway and Atherosclerosis
4 Chemokines and Atherosclerosis
5 Conclusions
Chapter Sixteen Nanotechnology Therapeutics in Oncology—Recent Developments and Future Outlook
1 Introduction
2 Passive Targeting—The EPR Effect
3 Ideal Characteristics of Nanoparticles
4 Loading of Nanoparticles
5 Types of Nanoparticles
6 The Next Generation of Nanomedicines for Oncology
7 Conclusions
Chapter Seventeen Small-Molecule Antagonists of Bcl-2 Family Proteins
1 Introduction
2 Small-Molecule Inhibitors of Bcl-2 Family Proteins
3 Conclusions
Chapter Eighteen Notch Pathway Modulators as Anticancer Chemotherapeutics
1 Introduction
2 Mechanism of Notch Signal Transduction
3 Role in Tumorigenesis
4 Inhibitors of Notch Signaling
5 Activators of Notch Signaling
6 Conclusions
Chapter Nineteen Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers
1 Introduction
2 Crizotinib (Xalkori®)
3 Acquired Crizotinib Resistance
4 Clinical Candidates
5 Preclinical Candidates
6 Conclusions
Chapter Twenty Recent Advances in the Discovery of Dengue Virus Inhibitors
1 Introduction
2 Viral Structural Protein Targets
3 Viral Nonstructural Protein Targets
4 Host Targets
5 Conclusions
Chapter Twenty-One Nonfluoroquinolone-Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
1 Introduction
2 Inhibition at the ATP-Binding Site
3 Inhibition at the Non-ATP-Binding Site
4 Conclusions
Chapter Twenty-Two HCV Inhibition Mediated Through the Nonstructural Protein 5A (NS5A) Replication Complex
1 Introduction
2 First-Generation NS5A Inhibitors
3 Current-Generation NS5A Inhibitors
4 NS5A Structural Biology and Current Inhibitor Design
5 Clinical Progress of NS5A Inhibitors
6 Future Prospects
Chapter Twenty-Three Antibody–Drug Conjugates for Targeted Cancer Therapy
1 Introduction
2 Target Selection
3 Cytotoxic Agents and Linkers Used in ADCs
4 Intracellular Catabolism of ADCs
5 ADCs in Clinical Development
6 Conclusion
Chapter Twenty-Four 3D Cell Cultures
1 Introduction
2 3D Cell Culture: A Physiologically Relevant Biological Tool to Investigate Cellular Behavior
3 Use of 3D Cell Cultures in Drug Discovery
4 Application of 3D Cell Cultures in Various Therapeutic Areas
5 Conclusion
Chapter Twenty-Five Virally Encoded G Protein-Coupled Receptors
1 Introduction
2 Structure, Function, and Physiological Consequences of vGPCRs
3 Allosteric Modulators of vGPCRs
4 Allosteric Modulators of vGPCRs at Work
5 Conclusions
Chapter Twenty-Six Recent Advances in Wnt/β-Catenin Pathway Small-Molecule Inhibitors
1 Introduction
2 Regulation of β-Catenin
3 Selective Small-Molecule Antagonists of Wnt/β-Catenin Signaling
4 Conclusions
Chapter Twenty-Seven Targeted Covalent Enzyme Inhibitors
1 Introduction
2 Functionally Reversible Covalent Enzyme Inhibitors
3 Functionally Irreversible Covalent Enzyme Inhibitors
4 Conclusions
Chapter Twenty-Eight Drug Design Strategies for GPCR Allosteric Modulators
1 Introduction
2 Structure–Activity Relationships of Allosteric Ligands
3 Functional Selectivity
4 What to Optimize: IC50? EC50? EMAX? Fold-Shift? Log(αβ)?
5 Do In Vitro Profiles Translate to In Vivo Pharmacology?
6 Assessing Allosteric Site Occupancy Through Radioligands and Pet Agents
7 Medicinal Chemistry Strategies for Allosteric Ligands
8 Conclusions
Chapter Twenty-Nine Progress in the Development of Non-ATP-Competitive Protein Kinase Inhibitors for Oncology
1 Introduction
2 Inhibition of Cyclin-Dependent Kinases Through the Cyclin Groove
3 Alternative Strategies in the Development of Non-ATP-Competitive CDK Inhibitors
4 Polo-Box Domain Inhibitors of Polo-Like Kinases
5 Conclusions
Chapter Thirty New Chemical Entities Entering Phase III Trials in 2011
1 Selection Criteria
2 Facts and Figures
3 NCE List
Chapter Thirty-One To Market, To Market—2011
Overview
1 Abiraterone Acetate (Anticancer)7–14
2 Aflibercept (Ophthalmologic, Macular Degeneration)15–22
3 Apixaban (Antithrombotic)23–37
4 Avanafil (Male Sexual Dysfunction)38–45
5 Azilsartan Medoxomil (Antihypertensive)46–52
6 Belatacept (Immunosupressive)53–61
7 Belimumab (Immunosuppressive, Lupus)62–68
8 Boceprevir (Antiviral)69–77
9 Brentuximab Verdotin (Anticancer)78–83
10 Crizotinib (Anticancer)84–89
11 Edoxaban (Antithrombotic)24–27,32,90–96
12 Eldecalcitol (Osteoporosis)97–102
13 Fidaxomicin (Antibacterial)103–108
14 Gabapentin Enacarbil (Restless Leg Syndrome)109–117
15 Iguratimod (Antiarthritic)118–124
16 Ipilimumab (Anticancer)78,125–131
17 Linagliptin (Antidiabetic)132–140
18 Mirabegron (Urinary Tract/Bladder Disorders)141–144
19 Retigabine (Anticonvulsant)145–156
20 Rilpivirine (Antiviral)4,157–165
21 Ruxolitinib (Anticancer)166–171
22 Tafamidis Meglumine (Neurodegeneration)172–176
23 Telaprevir (Antiviral)69,70,177–183
24 Vandetanib (Anticancer)184–189
25 Vemurafenib (Anticancer)190–195
26 Vilazodone Hydrochloride (Antidepressant)196–204
Keyword Index, Volume 47
Cumulative Chapter Titles Keyword Index, Volume 1 – 47
Cumulative NCE Introduction Index, 1983-2011
Cumulative NCE Introduction Index, 1983-2011 (by indication)
- No. of pages: 472
- Language: English
- Edition: 1
- Volume: 47
- Published: October 8, 2012
- Imprint: Academic Press
- Paperback ISBN: 9780123964922
- eBook ISBN: 9780123972149
JM
John E. Macor
Affiliations and expertise
Neuroscience Discovery Chemistry, Bristol-Myers Squibb, USARead Annual Reports in Medicinal Chemistry on ScienceDirect